Similar articles

• Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.

  Zimmerman TR Jr, Sage JI, Lang AE, Mark MH. Zimmerman TR Jr, et al. Mov Disord. 1994 Mar;9(2):173-7. doi: 10.1002/mds.870090208. Mov Disord. 1994. PMID: 8196678
• Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.

  Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Marconi R, et al. Mov Disord. 1994 Jan;9(1):2-12. doi: 10.1002/mds.870090103. Mov Disord. 1994. PMID: 8139601
• [Motor complications in patients with Parkinson disease treated with levodopa].

  Luquin MR, Obeso JA, Martínez-Lage JM. Luquin MR, et al. Neurologia. 1989 Jan-Feb;4(1):4-11. Neurologia. 1989. PMID: 2631806 Spanish.
• The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.

  Vidailhet M, Bonnet AM, Marconi R, Durif F, Agid Y. Vidailhet M, et al. Mov Disord. 1999;14 Suppl 1:13-8. Mov Disord. 1999. PMID: 10493399 Review. No abstract available.
• L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.

  Rascol O. Rascol O. Mov Disord. 1999;14 Suppl 1:19-32. Mov Disord. 1999. PMID: 10493400 Review. No abstract available.